Your email has been successfully added to our mailing list.

×
0.000825400319154821 0.001760854014197 0.00341165465250649 0.00423705497166131 -0.00121058713476035 -0.00286138777306984 -0.000110053375887205 0.00855664997523803
Stock impact report

Kashiv BioSciences and MS Pharma Enter into MENA License and Supply Agreement for ADL-018, Biosimilar Candidate to XOLAIR® (bOmalizumab) [Yahoo! Finance]

IQVIA Holdings, Inc. (IQV) 
Last iqvia holdings, inc. earnings: 4/28 07:00 am Check Earnings Report
US:NYSE Investor Relations: ir.iqvia.com
Company Research Source: Yahoo! Finance
PISCATAWAY, N.J., August 05, 2025 BUSINESS WIRE )--Kashiv BioSciences, LLC and MS Pharma today announced that the companies have entered into a license and supply agreement for ADL-018, Kashiv BioSciences' biosimilar candidate to XOLAIR® (bOmalizumab) in the Middle East and North Africa (MENA) region. IQVIA reported global sales of ~$4.5 billion and ~$60 million in MENA in 2024. Show less Read more
Impact Snapshot
Event Time:
IQV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for IQV alerts
Opt-in for
IQV alerts

from News Quantified
Opt-in for
IQV alerts

from News Quantified